Clinical trials: HIV-1
HIV
The Effect of Hyperbilirubinemia on CV Disease, Neurocog Function and Renal Function
Use of some protease inhibitors is associated with elevations of a blood pigment called bilirubin. This may occasionally lead to yellowing of the eyes (scleral icterus) or jaundice, but in the general population bilirubin…
- Trial name
- SSAT044 (NCT01475240)
- Where
- United Kingdom
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- St Stephens Aids Trust
HIV Infections
Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults
The purpose of this study is to determine the safety of and immune response to an investigational HIV vaccine, VRC-HIVADV014-00-VP, with or without a second investigational HIV vaccine, VRC-HIVDNA016-00-VP, in HIV uninfected…
- Trial name
- NCT00124007
- Testing
- VRC-HIVADV014-00-VP, VRC-HIVDNA016-00-VP
- Where
- 3 sites in Kenya, Rwanda
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1
Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of the potent, broadly neutralizing anti-HIV monoclonal antibodies (mAb) PGT121.414.LS alone and in combination with VRC07-523LS soon after birth in…
- Trial name
- NCT06517693
- Testing
- PGT121.414.LS, VRC07-523LS
- Where
- 17 sites in United States, Brazil and 4 more
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
Modelling the Interaction Between Rationally-designed Synthetic Model Viral Protein Immunogens
The objective of this experimental medicine study is to determine the extent to which different prime-boost combinations influence serum neutralising antibody breadth and associated B and T cells responses.
- Trial name
- EAVI2020_01 (NCT03816137)
- Testing
- ConM SOSIP, EDC ConM SOSIP, ConS UFO
- Where
- United Kingdom
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Imperial College London
HIV
Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine
This is a dose escalation study to test the safety and immunogenicity of an oral HIV-1 vaccine.
- Trial name
- NCT02366013
- Testing
- rcAd26.MOS1.HIV-Env 1x10^8 vp, rcAd26.MOS1.HIV-Env 1x10^9 vp, rcAd26.MOS1.HIV-Env 1x10^10 vp
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
HIV
Study to Evaluate the Dosage and Safety of Two Intramuscular Injections of an Investigational Clade B HIV Vaccine
This study aimed to evaluate the safety and reactogenicity of two intramuscular injections of two different dosages of an investigational clade B HIV vaccine.
- Trial name
- NCT01320176
- Testing
- Investigational HIV vaccine dose A, Investigational HIV vaccine dose B
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
HIV Infections
Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults
The purpose of this study is to test the safety of an HIV DNA vaccine (EP HIV-1090) and to test whether or not the vaccine can stimulate immune system responses in HIV uninfected people.
- Trial name
- NCT00054860
- Testing
- EP HIV-1090
- Where
- 5 sites in United States, Botswana
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules
To evaluate the safety and immunogenicity of an accelerated schedule of recombinant canarypox vaccine ALVAC-HIV MN120TMG (vCP205) versus control followed by boost with rgp120/HIV-1 SF2 vaccine in HIV-negative volunteers.
- Trial name
- NCT00001076
- Testing
- ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
- Where
- 3 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1
This study is testing a lab-made antibody called ePGT121v1-LS that targets a specific part of HIV. Researchers will give it by vein (IV) and under the skin (SC), both on its own and together with two other antibodies, VRC07-523LS…
- Trial name
- NCT07390955
- Testing
- ePGT121v1-LS (IV), PGDM1400LS (IV), VRC07-523LS (IV)
- Where
- 11 sites in United States, Peru and 1 more
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS, HIV Infections
Proviral DNA as a Target for HIV-1 Resistance Analysis
In summary, in this project the investigators propose to study the proviral DNA genotyping to implement a lower cost and wider than the commercial systems currently in use, in order to analyze all HIV genes that are therapeutic…
- Conditions
- HIV/AIDS, HIV Infections, HIV Seropositivity, Viral Infection
- Trial name
- HIV (NCT04088916)
- Where
- 2 sites in Chile
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- University of Chile
Pregnancy, HIV-1-infection
Pre-Exposure Prophylaxis Dosing in Pregnancy to Optimize HIV Prevention (PREP-P)
This trial is a prospective, multi-center, randomized comparison study of 2 Pre-Exposure Prophylaxis (PrEP) pharmacokinetic (PK) dosing regimens from 1st trimester through 12 weeks following delivery (postpartum) to achieve study…
- Trial name
- NCT03834909
- Testing
- Standard dose Truvada®, Pregnancy-adjusted dose Truvada®
- Volunteers
- healthy volunteers welcome
- Sponsor
- Johns Hopkins University
HIV Infections, HIV Seronegativity
Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa
The main goal of this study is to find out how the immune system responds to a specific type of HIV infection, known as C HIV-1, in order to develop a vaccine against this type of infection.
- Trial name
- NCT00006298
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immune Deficiency, HIV-related Gut Disease - Cause Unknown
Immune Activation in HIV-1 Infected Patients Under AntiRetroviral Treatment
Immune Activation persists in HIV-1 infected patients despite efficient antiretroviral treatment. This immune activation is responsible for immune deficiency as well as for non-AIDS related comorbidities, such as non-alcoholic…
- Conditions
- Immune Deficiency, HIV-related Gut Disease - Cause Unknown, Activation of Latent Virus, Other Diagnoses, Comorbidities, and Complications
- Trial name
- ACTIVIH (NCT02334943)
- Testing
- Blood test
- Where
- France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
HIV Infections
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
The purpose of this study is to find out whether these powerful combinations of anti-HIV drugs are safe and effective for use in patients in the early stages of HIV infection and to find out how patients' immune systems react to…
- Trial name
- NCT00001119
- Testing
- Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine
- Where
- 12 sites in United States, Australia
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients
Concomitant administration of recombinant human growth hormone (rhGH) may boost the expansion of immune reconstitution and broaden specific T cell responses not achievable by vaccination alone.
- Trial name
- NCT00287677
- Testing
- recombinant human Growth Hormone, Vaccination, HAART
- Where
- 2 sites in Spain
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Germans Trias i Pujol Hospital
Human Immunodeficiency Virus Type 1 (HIV-1)
Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat
The purpose of the study is to compare the pharmacokinetics and bioequivalence of atazanavir in a fixed-dose combination with cobicistat with that of atazanavir coadministered with cobicistat as single agents.
- Trial name
- Atazanavir (NCT01837719)
- Testing
- Atazanavir, Cobicistat, Atazanavir/Cobicistat FDC
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Bacterial Vaginosis, Vaginal Discharge
Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue
This is a research study to determine whether bacterial vaginosis (BV) changes the cervico-vaginal tissue (skin covering the cervix and vagina) and makes women at higher risk for getting HIV (Human Immunodeficiency Virus).
- Trial name
- CONRADBV (NCT01347632)
- Testing
- Metronidazole
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- CONRAD
HIV Infections, Malaria
Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients
Malarone® (atovaquone/proguanil) is frequently used in malaria prophylaxis. Unfortunately, there are indications that certain anti-HIV agents may decrease atovaquone plasma levels by induction of atovaquone metabolism.
- Trial name
- NCT00421473
- Testing
- Atovaquone / Proguanil
- Where
- 5 sites in Netherlands
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Human Immunodeficiency Virus (HIV) Infections
A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)
The primary objective of this study is to evaluate the safety and tolerability of Islatravir (ISL) in trans and gender diverse (TGD) participants who are receiving gender-affirming hormone therapy (GAHT) and are at low-risk for…
- Trial name
- NCT05130086
- Testing
- Islatravir
- Volunteers
- healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections, HIV Seronegativity
Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia
Tenofovir disoproxil fumarate (also known as tenofovir DF or Viread) is used with other anti-HIV drugs to treat HIV infection. Taking tenofovir DF every day may also prevent HIV infection.
- Trial name
- NCT00078182
- Testing
- Tenofovir DF
- Where
- Cambodia
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)